GP

Goudy Park Capital

North America, Illinois, United States, Chicago

Description

Goudy Park Capital is an investment advisory firm based in Chicago, Illinois.

Investor Profile

Goudy Park Capital has made 3 investments, with 0 in the past 12 months and 0% as lead.

Stage Focus

  • Series C (33%)
  • Series B (33%)
  • Series A (33%)

Country Focus

  • United States (100%)

Industry Focus

  • Biopharma
  • Biotechnology
  • Health Care
  • Medical
  • Therapeutics
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Goudy Park Capital frequently co-invest with?

New Leaf Venture Partners
North America, New York, United States, New York
Co-Investments: 2
Frazier Healthcare Partners
North America, Washington, United States, Seattle
Co-Investments: 2
Genesys Capital
North America, Ontario, Canada, Toronto
Co-Investments: 2
Longitude Capital
North America, California, United States, Menlo Park
Co-Investments: 2
OUP (Osage University Partners)
North America, Pennsylvania, United States, Bala Cynwyd
Co-Investments: 2
Beecken Petty O'Keefe & Company
North America, Illinois, United States, Chicago
Co-Investments: 2
Adams Street Partners
North America, Illinois, United States, Chicago
Co-Investments: 3
Baxter Ventures
North America, Illinois, United States, Deerfield
Co-Investments: 1
Latterell Venture Partners
North America, California, United States, San Francisco
Co-Investments: 3
P
North America, Illinois, United States, Northbrook
Co-Investments: 3

What are some of recent deals done by Goudy Park Capital?

Aptinyx

Evanston, Illinois, United States

Aptinyx Inc. is a biopharmaceutical company.

BiopharmaBiotechnologyHealth CareMedical
Series BDec 18, 2017
Amount Raised: $70,000,000
Aptinyx

Evanston, Illinois, United States

Aptinyx Inc. is a biopharmaceutical company.

BiopharmaBiotechnologyHealth CareMedical
Series AMay 10, 2016
Amount Raised: $65,000,000
Naurex

Evanston, Illinois, United States

Naurex is a clinical-stage company developing novel therapeutics for depression and other CNS disorders.

BiopharmaBiotechnologyTherapeutics
Series CDec 3, 2014
Amount Raised: $80,000,000